You are currently viewing Rising Healthcare Costs Driving Up Auto Insurance Premiums – Don’t Stipulate to Medical Bills in Bodily Injury Litigation
A medical billing expert can opine regarding reasonable charges for medical bills keeping insurance premiums down

Rising Healthcare Costs Driving Up Auto Insurance Premiums – Don’t Stipulate to Medical Bills in Bodily Injury Litigation

Michael F. Arrigo

Managing Partner, No World Borders, Inc.
LinkedIn: linkedin.com/in/marrigo

Rising Healthcare Costs Driving Up Auto Insurance Premiums Don’t Stipulate to Medical Bills in Bodily Injury Litigation

While inflation and higher repair costs certainly play a role in some premium pressures, my 15 years of experience as an expert witness in usual, customary, and reasonable (UCR) charges for medical bills in personal-injury and auto-liability cases shows that systemic issues in how bodily-injury (BI) claims are valued and litigated are a far more significant driver of rising auto insurance premiums than general inflation.

In many states, 150-year-old precedents under the collateral-source rule and related doctrines prevent juries or arbitrators from hearing evidence of what health insurers or auto carriers actually reimburse for the same services. This leaves inflated “list prices” or “chargemaster” amounts unchallenged as the default valuation methodology. Compounding this, plaintiffs’ counsel in numerous jurisdictions routinely use medical billing liens or letters of protection (LOPs) to route care outside the patient’s health insurance entirely. Providers then bill at full rack rates rather than negotiated insurance rates—often 2–4× higher—knowing the lien will be satisfied from the tort settlement or verdict. These practices artificially inflate the “reasonable value” of medical bills presented at trial or mediation.

Additionally, I routinely see treatment for pre-existing, non-accident-related conditions (degenerative spine issues, prior orthopedic complaints, chronic pain syndromes, etc.) being attributed to the minor auto accident in question. When these unrelated services are bundled into the BI claim without clear causation documentation, the claimed damages balloon—sometimes by tens of thousands of dollars per case. Because these inflated bills become the anchor for settlement negotiations and jury awards, insurers’ loss ratios on BI coverage climb even as overall accident frequency may be stable or declining.

This dynamic—more than raw inflation—is what I see driving the upward trend in BI claims costs that insurers are reporting nationwide.1 Objective research and industry analyses confirm that rising healthcare costs and medical claim severity are key contributors to higher auto insurance premiums nationwide.2

The result is higher premiums for all drivers, but especially urban, high-risk, and certain-state residents, where these litigation practices are most entrenched.

Both plaintiff and defense counsel serve their clients best when they obtain an independent UCR expert early. I am retained equally by plaintiffs’ firms (to document and defend the true market value of necessary care) and by defense carriers and counsel (to rebut inflated billing). Plaintiff attorneys absolutely have the right—and the duty—to advocate vigorously for their clients. Reasonable, medically necessary charges that are causally linked (based on testimony of medical professionals in an IME report, or others) to the accident and supported by proper documentation and reasonable charges (as assessed by a medical billing expert witness) may be fully recoverable. An objective UCR analysis simply ensures that the recoverable amount reflects what the community actually pays for the same services, rather than an artificial rack-rate figure shielded from market reality.

Particularly in jurisdictions such as New York, where the parties have previously stipulated to the reasonableness of medical bills, counsel on both sides may be leaving significant value on the table if the bills in question exceed $150,000. In those cases, retaining a qualified expert who can opine on the usual, customary, and reasonable (UCR) charges—without any reference to what insurance may pay, consistent with collateral-source rules—frequently demonstrates that the stipulated amounts substantially exceed true market norms. Plaintiffs’ counsel can use this to strengthen and defend a higher (but still evidence-based) demand; defense counsel can use it to negotiate more realistic settlements or prepare more effective cross-examination. Either way, the expert’s testimony stays fully compliant with the jurisdiction’s evidentiary limitations while delivering far greater precision than a blanket stipulation.

For more information on my services as a medical billing expert witness, visit our dedicated page.

Recent tort reform efforts, such as those in Florida, show how states are beginning to address inflated medical billing practices in auto cases.

Insurers can and should continue adjusting underwriting, but the long-term solution lies in greater transparency around medical-bill valuation. Until states modernize the rules of evidence to allow actual reimbursement data (where permissible) or encourage early expert involvement, BI severity will keep outpacing inflation and pushing auto insurance premiums higher into 2026 and beyond. I stand ready to assist counsel on either side in reaching fair, evidence-based resolutions.

Footnotes & Citations

  1. Insurance Information Institute (III), Facts & Statistics: Auto insurance (2024 data showing bodily injury claim severity at $28,278).
  2. Bankrate (2025), “Rising Healthcare Costs Are Driving Up Your Auto Insurance Rate,” citing CCC Intelligent Solutions data (35% increase in average BI claim payouts Q3 2023–Q1 2025); supported by III studies showing inflation added $76+ billion to personal auto liability losses 2014–2023 and NAIC 2022/2023 Auto Insurance Database Report (liability incurred losses up 9.4% to $120.5B).

Michael F. Arrigo

Michael Arrigo, an expert witness, and healthcare executive, brings four decades of experience in the software, financial services, and healthcare industries. In 2000, Mr. Arrigo founded No World Borders, a healthcare data, regulations, and economics firm with clients in the pharmaceutical, medical device, hospital, surgical center, physician group, diagnostic imaging, genetic testing, health I.T., and health insurance markets. His expertise spans the federal health programs Medicare and Medicaid and private insurance. He advises Medicare Advantage Organizations that provide health insurance under Part C of the Medicare Act. Mr. Arrigo serves as an expert witness regarding medical coding and billing, fraud damages, and electronic health record software for the U.S. Department of Justice. He has valued well over $1 billion in medical billings in personal injury liens, malpractice, and insurance fraud cases. The U.S. Court of Appeals considered Mr. Arrigo's opinion regarding loss amounts, vacating, and remanding sentencing in a fraud case. Mr. Arrigo provides expertise in the Medicare Secondary Payer Act, Medicare LCDs, anti-trust litigation, medical intellectual property and trade secrets, HIPAA privacy, health care electronic claim data Standards, physician compensation, Anti-Kickback Statute, Stark law, the Affordable Care Act, False Claims Act, and the ARRA HITECH Act. Arrigo advises investors on merger and acquisition (M&A) diligence in the healthcare industry on transactions cumulatively valued at over $1 billion. Mr. Arrigo spent over ten years in Silicon Valley software firms in roles from Product Manager to CEO. He was product manager for a leading-edge database technology joint venture that became commercialized as Microsoft SQL Server, Vice President of Marketing for a software company when it grew from under $2 million in revenue to a $50 million acquisition by a company now merged into Cincom Systems, hired by private equity investors to serve as Vice President of Marketing for a secure email software company until its acquisition and multi $million investor exit by a company now merged into Axway Software S.A. (Euronext: AXW.PA), and CEO of one of the first cloud-based billing software companies, licensing its technology to Citrix Systems (NASDAQ: CTXS). Later, before entering the healthcare industry, he joined Fortune 500 company Fidelity National Financial (NYSE: FNF) as a Vice President, overseeing eCommerce solutions for the mortgage banking industry. While serving as a Vice President at Fortune 500 company First American Financial (NYSE: FAF), he oversaw eCommerce and regulatory compliance technology initiatives for the top ten mortgage banks and led the Sarbanes Oxley Act Section 302 internal controls I.T. audit for the company, supporting Section 404 of the Sarbanes Oxley Act. Mr. Arrigo earned his Bachelor of Science in Business Administration from the University of Southern California. Before that, he studied computer science, statistics, and economics at the University of California, Irvine. His post-graduate studies include biomedical ethics at Harvard Medical School, biomedical informatics at Stanford Medical School, blockchain and crypto-economics at the Massachusetts Institute of Technology, and training as a Certified Professional Medical Auditor (CPMA). Mr. Arrigo is qualified to serve as a director due to his experience in healthcare data, regulations, and economics, his leadership roles in software and financial services public companies, and his healthcare M&A diligence and public company regulatory experience. Mr. Arrigo is quoted in The Wall Street Journal, Fortune Magazine, Kaiser Health News, Consumer Affairs, National Public Radio (NPR), NBC News Houston, USA Today / Milwaukee Journal Sentinel, Medical Economics, Capitol ForumThe Daily Beast, the Lund Report, Inside Higher Ed, New England Psychologist, and other press and media outlets. He authored a peer-reviewed article regarding clinical documentation quality to support accurate medical coding, billing, and good patient care, published by Healthcare Financial Management Association (HFMA) and published in Healthcare I.T. News. Mr. Arrigo serves as a member of the board of directors of a publicly traded company in the healthcare and data analytics industry, where his duties include: member, audit committee; chair, compensation committee; member, special committee.

Leave a Reply